Chinese-produced Covid-19 vaccine Sinopharm is still required to undergo a series of regulatory processes despite being included in the World Health Organization’s emergency use listing (EUL).

“Ito’y malaking tulong dahil na-review na siya ng mga eksperto ng WHO. So pagpasok dito sa bansa, regular process pa rin. Although siyempre malaking karagdagan sa credibility nu’ng nakapagbigay ang WHO ng EUL para sa bakunang ito,” Department of Health (DOH) Undersecretary Maria Rosario Vergeire said during a virtual briefing.

The usual regulatory procedure will make sure that Sinopharm will be given with an emergency use authorization (EUA), Vergeire added.

The WHO had earlier given emergency use to the vaccines produced by Pfizer-BioNTech, Moderna, Johnson and Johnson, and the AstraZeneca, being developed at separate sites in India and South Korea. 

Meanwhile, two to three companies applied with the FDA for an emergency use authorization (EUA) on Sinopharm.

The said companies have yet to process and submit the necessary requirements for the EUA. Ronald dela Cruz